Lupin Launches Glucagon Generic in US
x
Lupin introduces generic Glucagon for Injection USP in the US market. Bioequivalent to Eli Lilly's, used for hypoglycemia treatment.
New Delhi, Aug 11 (PTI) Drug maker Lupin on Monday said it has launched a medication, used to regulate blood glucose levels, in the US market.
The company has launched Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the US, the Mumbai-based drug maker said in a statement.
The company's product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, it added.
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
As per IQVIA MAT June data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the US.
The company has launched Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the US, the Mumbai-based drug maker said in a statement.
The company's product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, it added.
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
As per IQVIA MAT June data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the US.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone-Idea-L
- 11.25 (+ 4.85)
- 124593459
- Mangalam-Industrial
- 0.90 (+ 4.65)
- 43018654
- Welcure-Drugs-and
- 0.50 (+ 4.17)
- 39983710
- Alstone-Textiles
- 0.29 ( -3.33)
- 27516634
- Murae-Organisor
- 0.27 (+ 3.85)
- 26520405
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback